Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement

Clin Ther. 2008 Sep;30(9):1687-99. doi: 10.1016/j.clinthera.2008.09.012.

Abstract

Background: Recombinant human growth hormone (r-hGH) is increasingly being used in children. Although growth hormone (GH) may alter the clearance of concomitantly administered medications, its effects on individual drug-metabolizing enzymes in children have not been characterized.

Objective: The goal of this study was to assess the activities of cytochrome P450 (CYP) 1A2, N-acetyltransferase 2, xanthine oxidase, and CYP2D6 in children with isolated idiopathic GH deficiency before and 3 and 6 months after initiation of r-hGH treatment.

Methods: This 6-month, prospective, longitudinal, open-label phenotyping study was conducted at 4 academic tertiary care centers within the Pediatric Pharmacology Research Unit network. Prepubertal or early pubertal children (4-14 years) with short stature and isolated idiopathic GH deficiency were enrolled. Patients were given 4 ounces of a cola beverage and 0.5 mg/kg of dextromethorphan (DM) before and 3 and 6 months after initiation of r-hGH treatment. Urine was collected for 8 hours after probe substrate administration, and enzyme activity was assessed using validatedcaffeine/metaboliteandDM/metabolitemolar ratios. Patients with a DM/dextrorphan molar ratio > or =0.3 were classified as poor metabolizers, and those with a ratio <0.3 were classified as extensive metabolizers. Anthropometric and biochemical responses were assessed at each visit. Blood was also obtained for determination of serum insulinlike growth factor-1 (IGF-1) levels and CYP2D6 genotype.

Results: Fourteen patients (mean [SD] age, 11.5 [2.6] years [age range, 4.5-14.6 years]; 11 males, 3 females; 100% white; median height and weight, 131.8 cm and 29.2 kg, respectively) completed the 3 study visits. However, data from 2 patients were excluded from analysis due to procedural violations. In all patients, growth velocity and serum IGF-1 concentrations were significantly higher (P < 0.001) after r-hGH treatment (mean doses, 0.32 and 0.33 mg/kg per week at 3 and 6 months, respectively). However, molar ratio values did not significantly change after initiation of r-hGH.

Conclusions: In this study population of children with isolated idiopathic GH deficiency, no significant differences in caffeine/metabolite and DM/metabolite molar ratios were observed after initiation of r-hGH treatment.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Arylamine N-Acetyltransferase / drug effects
  • Arylamine N-Acetyltransferase / metabolism
  • Caffeine / metabolism
  • Caffeine / urine*
  • Central Nervous System Stimulants / metabolism
  • Central Nervous System Stimulants / urine*
  • Child
  • Child, Preschool
  • Cytochrome P-450 CYP1A2 / drug effects
  • Cytochrome P-450 CYP1A2 / metabolism
  • Cytochrome P-450 CYP2D6 / drug effects
  • Cytochrome P-450 CYP2D6 / metabolism
  • Dextromethorphan / metabolism
  • Dextromethorphan / urine*
  • Dwarfism, Pituitary / drug therapy
  • Female
  • Growth Disorders / blood
  • Growth Disorders / drug therapy*
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / pharmacology*
  • Human Growth Hormone / therapeutic use
  • Humans
  • Insulin-Like Growth Factor I / analysis
  • Longitudinal Studies
  • Male
  • Phenotype
  • Prospective Studies
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology*
  • Recombinant Proteins / therapeutic use
  • Xanthine Oxidase / drug effects
  • Xanthine Oxidase / metabolism

Substances

  • Central Nervous System Stimulants
  • Recombinant Proteins
  • Human Growth Hormone
  • Caffeine
  • Insulin-Like Growth Factor I
  • Dextromethorphan
  • Cytochrome P-450 CYP1A2
  • Cytochrome P-450 CYP2D6
  • Xanthine Oxidase
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human